Keymed Biosciences Announces Interim Results for First Half of 2024 ...Middle East

PR Newswire - News
CHENGDU, China, Aug. 28, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced its interim results for the first half of 2024, along with a corporate update. Rapid development of our pipeline products Stapokibart (CM310) (IL-4Rα antibody) In June 2024, the long-term...

Hence then, the article about keymed biosciences announces interim results for first half of 2024 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Keymed Biosciences Announces Interim Results for First Half of 2024 )

Apple Storegoogle play

Last updated :

Also on site :